Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination
1996

Immune Responses in Pancreatic Cancer Patients After Ras Peptide Vaccination

Sample size: 2 publication Evidence: low

Author Information

Author(s): MK Gjertsen, I Saeterdal, E Thorsby, G Gaudernack

Primary Institution: Institute of Transplantation Immunology, The National Hospital, University of Oslo

Hypothesis

Can mutant ras peptide vaccination induce specific immune responses in pancreatic carcinoma patients?

Conclusion

The study demonstrated that ras peptide vaccination can induce T cells specific for mutant ras peptides in pancreatic cancer patients.

Supporting Evidence

  • Responding T cells from one patient were cloned, showing specific immune responses.
  • Different T-cell precursor frequencies were observed for mutant and normal ras peptides.
  • Vaccination resulted in clonal expansion of CD4+ T cells specific for the mutant ras peptide.

Takeaway

Doctors gave special shots to two patients with pancreatic cancer to help their bodies fight the cancer, and it worked by making their immune system recognize the cancer better.

Methodology

Patients were vaccinated with synthetic ras peptide-pulsed autologous antigen-presenting cells, and T-cell responses were analyzed through various assays.

Limitations

The study involved only two patients, limiting the generalizability of the results.

Participant Demographics

Two patients with unresectable pancreatic adenocarcinoma, aged 49 and 39.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication